No Prescription |
 |
 | ||
|
Catapres TTS 1 Generic Clonidine |
|
| ||
| Catapres TTS 1 Generic Clonidine Indications:CATAPRES-TTS is indicated for the treatment of mild to moderate hypertension. It can be used as monotherapy or concomitantly with other antihypertensive agents if required to enhance hypotensive effect.Dosage and Administration:CATAPRES-TTS dosage should be titrated according to individual patient's therapeutic requirements. Commence with one CATAPRES-TTS-1 applied weekly to a freshly cleaned hairless area of the upper outer arm or chest. A new site should be used each week when applying new patches. If after two to four weeks the desired reduction in blood pressure is not achieved increase the weekly dosage by changing to CATAPRES-TTS-2. If this dosage is still not satisfactory after 2-4 weeks therapy then increase the weekly dosage by changing to CATAPRES-TTS-3.Most patients with mild to moderate hypertension will be controlled on one CATAPRES-TTS-3 or less. In more resistant cases where blood pressure is not satisfactorily controlled on one CATAPRES-TTS-3 it is recommended that a diuretic and/or other antihypertensive agents be added to enhance the hypotensive effect. In this way the dose of each individual drug may be reduced and side effects minimised. Higher doses of up to two CATAPRES-TTS-3 a week have been utilised.When substituting CATAPRES-TTS in patients on prior oral antihypertensive therapy including oral CATAPRES physicians should be aware that the antihypertensive effect of CATAPRES-TTS might not commence until 2-3 days after initial application. Therefore gradual reduction of prior drug dosage over 5-6 days is advised.Instructions on correct application of CATAPRES-TTS are provided on a separate patient leaflet. Buy Catapres TTS 1 Generic Clonidine and other Prescription Drugs 4 products online at Medstore. 5462
About Catapres TTS 1 Generic Clonidine: Product Type: Prescription Drugs 4 Catapres TTS-1 ( Generic Clonidine ) Catapres TTS-1 (Generic Clonidine) Generic Clonidine 2.5mg 4 Patches Generic Clonidine Catapres TTS-1
No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
|
|
|